Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.
Richter, Joshua
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. [electronic resource] - Blood Jan 2013 - 423-30 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1528-0020
10.1182/blood-2012-06-435503 doi
Aged
Antineoplastic Agents--therapeutic use
Combined Modality Therapy
Dendritic Cells--cytology
Drug Synergism
Female
Galactosylceramides--metabolism
Humans
Killer Cells, Natural--drug effects
Lenalidomide
Lymphocyte Activation--drug effects
Male
Middle Aged
Monocytes--cytology
Multiple Myeloma--drug therapy
Thalidomide--analogs & derivatives
Treatment Outcome
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. [electronic resource] - Blood Jan 2013 - 423-30 p. digital
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1528-0020
10.1182/blood-2012-06-435503 doi
Aged
Antineoplastic Agents--therapeutic use
Combined Modality Therapy
Dendritic Cells--cytology
Drug Synergism
Female
Galactosylceramides--metabolism
Humans
Killer Cells, Natural--drug effects
Lenalidomide
Lymphocyte Activation--drug effects
Male
Middle Aged
Monocytes--cytology
Multiple Myeloma--drug therapy
Thalidomide--analogs & derivatives
Treatment Outcome